Parnax Lab Limited (BOM:506128)

Market Cap	1.53B +49.5%
Revenue (ttm)	2.28B +23.1%
Net Income	125.20M +15.5%
EPS	10.90 +15.5%
Shares Out	11.49M
PE Ratio	12.21
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	17,294
Average Volume	4,596
Open	146.80
Previous Close	122.50
Day's Range	124.20 - 146.80
52-Week Range	85.60 - 146.80
Beta	-0.07
RSI	57.45
Earnings Date	May 29, 2026

About Parnax Lab

Parnax Lab Limited engages in the manufacture and export of pharmaceutical formulations in India and internationally. The company offers pharmaceutical products in the form of liquids, ointments, gels, creams, tablets, and capsules; cosmetic products; herbal products; and nutraceutical products. It also provides Oral Formulations, such as cough expectorants, antacids, antihistamines, multi-vitamins, enzyme preparations, pediatric formulations, formulations for geriatrics, highly viscous products, and suspensions. In addition, the company provid...

• Industry: Pharmaceutical Preparations
• Founded: 1982
• Employees: 12
• Stock Exchange: Bombay Stock Exchange
• Ticker Symbol: 506128

Financial Performance

In fiscal year 2025, Parnax Lab's revenue was 1.88 billion, a decrease of -0.54% compared to the previous year's 1.89 billion. Earnings were 115.19 million, an increase of 19.87%.